(Q27824855)

2

0 references

Ingo K Mellinghoff

3

0 references

Derek S Welsbie

4

0 references

Emily Chan

5

0 references

Barbara Fueger

6

0 references

Johannes Czernin

7

0 references

Charles L Sawyers

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

8

0 references

language of work or name

English

0 references

publication date

January 2006

0 references

published in

Nature Medicine

0 references

volume

12

0 references

page(s)

122-7

0 references

issue

1

0 references

cites work

1 reference

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation

21 January 2018

1 reference

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

21 January 2018

1 reference

Proline hydroxylation and gene expression

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

21 January 2018

1 reference

Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors

21 January 2018

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

Positron emission tomography for urological tumours

21 January 2018

1 reference

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

The hypoxic response of tumors is dependent on their microenvironment.

21 January 2018

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

Tantalum [18O]Water Target for the Production of [18F]Fluoride with High Reactivity for the Preparation of 2-Deoxy-2-[18F]Fluoro-D-Glucose

21 January 2018

1 reference